Dynavax Highlights 2022 Priorities and Announces Initiation of Phase 1 Clinical Trial for Its Shingles Vaccine Candidate

EMERYVILLE, Calif.: EMERYVILLE, Calif., Jan. 10, 2022 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial stage biopharmaceutical company focused on developing and commercializing innovative vaccines, today outlined its strategic priorities for 2022, and announced the newest candidate in its clinical development portfolio – a herpes zoster virus (shingles) vaccine...

Click to view original post